The Changing Face of HDL and the Best Way to Measure It.
暂无分享,去创建一个
[1] J. Otvos,et al. Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample. , 2016, Atherosclerosis.
[2] M. Connelly,et al. High-density lipoprotein and inflammation in cardiovascular disease. , 2016, Translational research : the journal of laboratory and clinical medicine.
[3] M. Budoff,et al. Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2016, The American journal of cardiology.
[4] J. Polak,et al. Concentration of Smaller High‐Density Lipoprotein Particle (HDL‐P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.
[5] A. Gotto,et al. Speciated High-Density Lipoprotein Biogenesis and Functionality , 2016, Current Atherosclerosis Reports.
[6] T. Hornemann,et al. Decreased phosphatidylcholine plasmalogens--A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. , 2016, Atherosclerosis.
[7] E. Grapsa,et al. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease , 2016, Renal failure.
[8] G. Franceschini,et al. Protective Effects of HDL Against Ischemia/Reperfusion Injury , 2016, Front. Pharmacol..
[9] P. Ridker,et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2015, Circulation.
[10] M. Gruchała,et al. PON-1 Activity and Plasma 8-Isoprostane Concentration in Patients with Angiographically Proven Coronary Artery Disease , 2015, Oxidative medicine and cellular longevity.
[11] D. Rader,et al. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. , 2015, Journal of the American College of Cardiology.
[12] N. Schneiderman,et al. HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. , 2015, Atherosclerosis.
[13] R. Erbel,et al. Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. , 2015, Journal of the American College of Cardiology.
[14] P. Ridker,et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial , 2015 .
[15] C. Shear,et al. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial , 2015, Journal of the American Heart Association.
[16] D. Rader,et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.
[17] A. Pitt,et al. Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology. , 2015, Antioxidants & redox signaling.
[18] M. Malkoç,et al. Pleiotropic eff ects of HDL subfractions and HDL-associated enzymes on protection against coronary artery disease , 2015, Acta cardiologica.
[19] D. Rader,et al. High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[20] G. Franceschini,et al. Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease , 2015, Journal of internal medicine.
[21] B. Vergès. Pathophysiology of diabetic dyslipidaemia: where are we? , 2015, Diabetologia.
[22] T. Murohara,et al. Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse cardiovascular events in patients with acute myocardial infarction. , 2015, The American journal of cardiology.
[23] J. Genest,et al. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk , 2015, BBA clinical.
[24] A. Tall,et al. Cholesterol, inflammation and innate immunity , 2015, Nature Reviews Immunology.
[25] A. Khera,et al. HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.
[26] Guohua Song,et al. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. , 2014, Biochimica et biophysica acta.
[27] H. Berrougui,et al. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients. , 2014, Clinical biochemistry.
[28] E. Soriano,et al. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. , 2014, Atherosclerosis.
[29] G. Jarvik,et al. Quantification of HDL particle concentration by calibrated ion mobility analysis. , 2014, Clinical chemistry.
[30] P. Wolf,et al. Antipsoriatic treatment extends beyond the skin: recovering of high‐density lipoprotein function , 2014, Experimental dermatology.
[31] J. Kastelein,et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. , 2014, British journal of clinical pharmacology.
[32] G. Norata,et al. HDL in innate and adaptive immunity. , 2014, Cardiovascular research.
[33] M. Phillips. Molecular Mechanisms of Cellular Cholesterol Efflux* , 2014, The Journal of Biological Chemistry.
[34] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[35] I. Holme,et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. , 2014, European heart journal.
[36] V. Falk,et al. TAVI in a low left main coronary artery ostium and wide aortic sinus of Valsava. , 2014, European heart journal.
[37] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[38] J. Suico,et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults , 2014, The Journal of pharmacy and pharmacology.
[39] B. Kingwell,et al. HDL-targeted therapies: progress, failures and future , 2014, Nature Reviews Drug Discovery.
[40] Kirsty Minton. Cell migration: Coordinating calcium signalling , 2014, Nature Reviews Molecular Cell Biology.
[41] R. Nieuwland,et al. Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation , 2014, Journal of extracellular vesicles.
[42] E. Latz,et al. High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3 , 2013, Nature Immunology.
[43] A. Nègre-Salvayre,et al. Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids: Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[44] A. Kontush,et al. Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.
[45] Tanya M. Teslovich,et al. Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.
[46] David C. Anderson,et al. Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides Impact on Global Health Outcome (AIM–HIGH) Trial , 2013, Stroke.
[47] P. Ridker,et al. Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis , 2013, Circulation.
[48] G. Franceschini,et al. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. , 2013, Cardiovascular research.
[49] P. Ridker,et al. High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.
[50] J. Varshosaz,et al. Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome. , 2013, Acta medica Iranica.
[51] J. Voss,et al. The secondary structure of apolipoprotein A-I on 9.6-nm reconstituted high-density lipoprotein determined by EPR spectroscopy , 2013, The FEBS journal.
[52] K. Koh,et al. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. , 2013, International journal of cardiology.
[53] K. Moore,et al. Dysfunctional HDL takes its toll in chronic kidney disease. , 2013, Immunity.
[54] M. Saemann,et al. Inflammation alters HDL composition and function: implications for HDL-raising therapies. , 2013, Pharmacology & therapeutics.
[55] R. Hegele,et al. HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. , 2013, Journal of clinical lipidology.
[56] G. Norata,et al. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.
[57] Jun Ren,et al. High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate , 2013, Cardiovascular Diabetology.
[58] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[59] K. Huber,et al. Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities , 2012, British journal of pharmacology.
[60] K. Zangger,et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. , 2012, Antioxidants & redox signaling.
[61] R. Birner-Gruenberger,et al. Psoriasis alters HDL composition and cholesterol efflux capacity[S] , 2012, Journal of Lipid Research.
[62] E. Eren,et al. High Density Lipoprotein and it’s Dysfunction , 2012, The open biochemistry journal.
[63] J. Ordóñez‐Llanos,et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. , 2012, The American journal of cardiology.
[64] D. Elashoff,et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. , 2012, Arthritis and rheumatism.
[65] L. Joosten,et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study , 2012, Arthritis Research & Therapy.
[66] N. Knowlton,et al. Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease , 2012, Scandinavian journal of rheumatology.
[67] W. Hörl,et al. Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.
[68] Swneke D. Bailey,et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. , 2012, Biochimica et biophysica acta.
[69] N. Webb,et al. Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI[S] , 2012, Journal of Lipid Research.
[70] B. Nordestgaard,et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.
[71] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[72] A. Clarke,et al. Effects of Wnt3A and mechanical load on cartilage chondrocyte homeostasis , 2011, Arthritis research & therapy.
[73] O. Yang,et al. A biochemical fluorometric method for assessing the oxidative properties of HDL[S] , 2011, Journal of Lipid Research.
[74] Ming-Dauh Wang,et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.
[75] R. Birner-Gruenberger,et al. Uremia alters HDL composition and function. , 2011, Journal of the American Society of Nephrology : JASN.
[76] G. Moneta. Correction for Feig et al., HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells , 2011, Proceedings of the National Academy of Sciences.
[77] A. Akhmedov,et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. , 2011, The Journal of clinical investigation.
[78] E. Schaefer,et al. Metabolic and functional relevance of HDL subspecies , 2011, Current opinion in lipidology.
[79] B. Nordestgaard,et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease , 2011, Lipids in Health and Disease.
[80] A. Nègre-Salvayre,et al. Oxidized LDLs trigger endoplasmic reticulum stress and autophagy: Prevention by HDLs , 2011, Autophagy.
[81] A. Nègre-Salvayre,et al. HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs , 2011, Cell Death and Differentiation.
[82] M. Kaplan,et al. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus , 2011, Arthritis research & therapy.
[83] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[84] W. Hörl,et al. The versatility of HDL: a crucial anti‐inflammatory regulator , 2010, European journal of clinical investigation.
[85] Koichi Sato,et al. Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein. , 2010, World journal of biological chemistry.
[86] L. Tian,et al. The relationship between high density lipoprotein subclass profile and plasma lipids concentrations , 2010, Lipids in Health and Disease.
[87] R. Hegele,et al. Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. , 2010, Journal of clinical lipidology.
[88] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.
[89] E. Schaefer,et al. Marked HDL deficiency and premature coronary heart disease , 2010, Current opinion in lipidology.
[90] P. Barter,et al. Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[91] M. Olivier,et al. Integrated approach for the comprehensive characterization of lipoproteins from human plasma using FPLC and nano-HPLC-tandem mass spectrometry. , 2010, Physiological genomics.
[92] Costantina Manes,et al. Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.
[93] Florian Kronenberg,et al. Emerging risk factors and markers of chronic kidney disease progression , 2009, Nature Reviews Nephrology.
[94] D. Sviridov,et al. Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux , 2009, Circulation.
[95] W. Hueb,et al. In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment , 2009, Lipids.
[96] A. Daugherty,et al. Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response* , 2009, The Journal of Biological Chemistry.
[97] Shuiping Zhao,et al. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. , 2009, Atherosclerosis.
[98] S. Hajduk,et al. Membrane Permeabilization by Trypanosome Lytic Factor, a Cytolytic Human High Density Lipoprotein* , 2009, Journal of Biological Chemistry.
[99] T. Mogensen. Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.
[100] A. Remaley,et al. Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. , 2009, Current opinion in endocrinology, diabetes, and obesity.
[101] M. Couturier,et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I , 2009, Journal of cellular and molecular medicine.
[102] N. Wareham,et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.
[103] D. Sviridov,et al. Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque , 2008, Circulation research.
[104] S. Hammad,et al. High Density Lipoprotein-associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function* , 2008, Journal of Biological Chemistry.
[105] J. Liao. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.
[106] B. Levkau. Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. , 2008, Circulation research.
[107] L. Badimón,et al. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.
[108] Børge G Nordestgaard,et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.
[109] S. Moestrup,et al. A Haptoglobin-Hemoglobin Receptor Conveys Innate Immunity to Trypanosoma brucei in Humans , 2008, Science.
[110] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events , 2008 .
[111] A. Tall,et al. Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.
[112] F. D. de Beer,et al. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. , 2008, The Journal of clinical investigation.
[113] S. Moestrup,et al. Hemoglobin Is a Co-Factor of Human Trypanosome Lytic Factor , 2007, PLoS pathogens.
[114] M. Couturier,et al. Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles: Relevance to Antiapoptotic and Antioxidative Activities , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[115] Subramaniam Pennathur,et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.
[116] N. Brunetti,et al. Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings. , 2007, European journal of internal medicine.
[117] Kimmo Kaski,et al. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. , 2007, Atherosclerosis.
[118] P. Barter,et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase , 2007, Diabetologia.
[119] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[120] G. Walldius,et al. The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.
[121] H. Bloomfield,et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.
[122] S. Hajduk,et al. Serum Resistance-Associated Protein Blocks Lysosomal Targeting of Trypanosome Lytic Factor in Trypanosoma brucei , 2006, Eukaryotic Cell.
[123] E. D. de Faria,et al. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. , 2005, Atherosclerosis.
[124] S. Hajduk,et al. Human High Density Lipoproteins Are Platforms for the Assembly of Multi-component Innate Immune Complexes* , 2005, Journal of Biological Chemistry.
[125] B. Hansel,et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.
[126] P. Barter,et al. Antiinflammatory Properties of HDL , 2004 .
[127] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[128] G. Norata,et al. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[129] S. Rusconi,et al. Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase , 2004, Circulation research.
[130] M. Elisaf,et al. Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study , 2004, Current medical research and opinion.
[131] G. Franceschini,et al. Synthetic High-Density Lipoproteins Exert Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury , 2004, Journal of Pharmacology and Experimental Therapeutics.
[132] P. Kovanen,et al. Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.
[133] A. Kontush,et al. Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[134] A. Remaley,et al. Binding and Internalization of Lipopolysaccharide by Cla-1, a Human Orthologue of Rodent Scavenger Receptor B1* , 2003, Journal of Biological Chemistry.
[135] M. Quon,et al. High Density Lipoprotein-induced Endothelial Nitric-oxide Synthase Activation Is Mediated by Akt and MAP Kinases* , 2003, The Journal of Biological Chemistry.
[136] R. Brasseur,et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.
[137] G. Franceschini,et al. High-Density Lipoproteins Protect Isolated Rat Hearts From Ischemia-Reperfusion Injury by Reducing Cardiac Tumor Necrosis Factor-&agr; Content and Enhancing Prostaglandin Release , 2003, Circulation research.
[138] G. Norata,et al. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. , 2002, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[139] F. Ruschitzka,et al. High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.
[140] C. Marchionni,et al. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity , 2001, Acta Diabetologica.
[141] A. von Eckardstein,et al. Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids* , 2001, The Journal of Biological Chemistry.
[142] S. Hajduk,et al. Haptoglobin-related Protein Mediates Trypanosome Lytic Factor Binding to Trypanosomes* , 2001, The Journal of Biological Chemistry.
[143] S. Reddy,et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.
[144] Richard G. W. Anderson,et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.
[145] J. Wittes,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.
[146] G. Dagenais,et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. , 2000, Atherosclerosis.
[147] B. Nordestgaard,et al. Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study , 2000, Circulation.
[148] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[149] K. Tsuchida,et al. High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-α-Induced Apoptosis , 2000 .
[150] S.-M. Kim,et al. Glycation impairs high-density lipoprotein function , 2000, Diabetologia.
[151] S. Lestavel,et al. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[152] J. Viikari,et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.
[153] J. Saklatvala,et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[154] M. Sata,et al. Endothelial Cell Apoptosis Induced by Oxidized LDL Is Associated with the Down-regulation of the Cellular Caspase Inhibitor FLIP* , 1998, The Journal of Biological Chemistry.
[155] A Pasternack,et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. , 1998, Circulation.
[156] J. E. Doran,et al. Reconstituted High Density Lipoprotein (rHDL) Modulates Platelet Activity In Vitro and Ex Vivo , 1998, Thrombosis and Haemostasis.
[157] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[158] A. van Tol,et al. Delayed increase in high density lipoprotein-phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. , 1998, Atherosclerosis.
[159] A. Nègre-Salvayre,et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[160] H. Hein,et al. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[161] J. E. Doran,et al. Differential Effects of Reconstituted High-density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia , 1997, Thrombosis and Haemostasis.
[162] R. Larkins,et al. Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. , 1996, The American journal of physiology.
[163] G. Dagenais,et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. , 1996, Atherosclerosis.
[164] J. Gamble,et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[165] T. Wilt,et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.
[166] G. Dagenais,et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) , 1995, The American journal of cardiology.
[167] S. Hajduk,et al. Killing of trypanosomes by the human haptoglobin-related protein. , 1995, Science.
[168] J. Berliner,et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.
[169] A. Tall. An overview of reverse cholesterol transport. , 1994, European heart journal.
[170] F. Fend,et al. HDL and plasma phospholipids in coronary artery disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[171] S. Hajduk,et al. Endocytosis of a cytotoxic human high density lipoprotein results in disruption of acidic intracellular vesicles and subsequent killing of African trypanosomes , 1994, The Journal of cell biology.
[172] C. Abbott,et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.
[173] K. Emancipator,et al. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins , 1992, Infection and immunity.
[174] A. Tall,et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. , 1991, Atherosclerosis.
[175] S. G. Rains,et al. Association of high density lipoprotein cholesterol with plasma lipolytic activity and C-peptide concentration in type 2 diabetes. , 1991, Diabetes research.
[176] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[177] G. Franceschini,et al. Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. , 1990, Atherosclerosis.
[178] Cruickshank Jm. Beta-blockers, plasma lipids, and coronary heart disease. , 1990 .
[179] H. Northoff,et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins , 1989, Infection and immunity.
[180] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[181] P. Wilson,et al. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.
[182] G. Coetzee,et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. , 1986, The Journal of biological chemistry.
[183] A. Tall,et al. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. , 1985, Journal of lipid research.
[184] J. Witztum,et al. Plasma Apolipoproteins AI, AII, B, CI, and E Are Glucosylated in Hyperglycemic Diabetic Subjects , 1985, Diabetes.
[185] R. Strunk,et al. Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. , 1983, Immunology.
[186] A. Tall,et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. , 1982, The Journal of biological chemistry.
[187] E. Lee,et al. Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. , 1981, Atherosclerosis.
[188] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[189] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.
[190] A. Gotto,et al. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. , 2015, Journal of clinical lipidology.
[191] L. Calabresi,et al. Structure of HDL: particle subclasses and molecular components. , 2015, Handbook of experimental pharmacology.
[192] G. Norata,et al. Emerging role of high density lipoproteins as a player in the immune system. , 2012, Atherosclerosis.
[193] B. Gersh. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease , 2011 .
[194] B. Gersh. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2011 .
[195] M. Phillips,et al. High density lipoprotein structure-function and role in reverse cholesterol transport. , 2010, Sub-cellular biochemistry.
[196] G. Moneta,et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .
[197] A. Esteghamati,et al. LECITHIN: CHOLESTEROL ACYLTRANSFERASE ACTIVITY IS DECREASED IN TYPE 2 DIABETES MELLITUS , 2007 .
[198] Loyd,et al. SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .
[199] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[200] K. Tsuchida,et al. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. , 2000, Biochemical and biophysical research communications.
[201] R. Ulevitch,et al. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.
[202] J. Cruickshank. Beta-blockers, plasma lipids, and coronary heart disease. , 1990, Circulation.